<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1868">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04352959</url>
  </required_header>
  <id_info>
    <org_study_id>BBCovid</org_study_id>
    <nct_id>NCT04352959</nct_id>
  </id_info>
  <brief_title>COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses</brief_title>
  <acronym>BBCovid</acronym>
  <official_title>COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses: Double-blind, Randomized, Placebo-controlled Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Claude Bernard University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Claude Bernard University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Given the current lack of effective COVID-19 treatment, it is necessary to explore
      alternative methods to contain the spread of the infection, focusing in particular on its
      mode of transmission. The modes of person-to-person transmission of SARS-CoV-2 are direct
      transmission, such as sneezing, coughing, transmission through inhalation of small droplets,
      and transmission through contact, such as contact with nasal, oral and eye mucous membranes.
      SARS-CoV-2 can also be transmitted directly or indirectly through saliva. The use of
      antiviral mouthrinses may be used as adjunctive therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2020</start_date>
  <completion_date type="Anticipated">December 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline amount of SARS-CoV-2 in salivary samples at 7 days</measure>
    <time_frame>7 days</time_frame>
    <description>Quantitative PCR experiments will be performed and a quantitative analysis of the salivary samples will be made</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline amount of SARS-CoV-2 virus in nasal samples at 7 days</measure>
    <time_frame>7 days</time_frame>
    <description>Quantitative PCR experiments will be performed and a quantitative analysis of the nasal samples will be made</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">206</enrollment>
  <condition>COVID19</condition>
  <condition>Mouthwash</condition>
  <condition>Saliva</condition>
  <arm_group>
    <arm_group_label>mouth rinse with antiviral</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>mouth rinse without antiviral</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>mouthrinse with bêta-cyclodextrin and citrox</intervention_name>
    <description>3 daily mouthrinses for 7 days</description>
    <arm_group_label>mouth rinse with antiviral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>mouthrinse without bêta-cyclodextrin and citrox</intervention_name>
    <description>3 daily mouthrinses for 7 days</description>
    <arm_group_label>mouth rinse without antiviral</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Covid-19 infection by the patient's general practitioner and
             hospital doctor

          -  Clinical signs started less than 48 hours ago.

          -  Virological confirmation: not necessary but possible.

          -  Understanding and acceptance of the trial.

          -  Written agreement to participate in the trial

        Exclusion Criteria:

          -  Pregnancy

          -  Breastfeeding

          -  Inability to comply with protocol

          -  Lack of written agreement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>florence Carrouel, PhD</last_name>
    <phone>0478785745</phone>
    <email>florence.carrouel@univ-lyon1.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinic of the Protestant Infirmary in Lyon</name>
      <address>
        <city>Caluire-et-Cuire</city>
        <zip>69300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herve Perrier</last_name>
      <email>recherche-clinique@infirmerie-protestante.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Emile Roux</name>
      <address>
        <city>Le Puy en Velay</city>
        <zip>43000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Lengagne</last_name>
      <phone>0471043704</phone>
      <email>sophie.lengagne@ch-lepuy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intercommunal Hospital Center of Mont de Marsan</name>
      <address>
        <city>Mont de Marsan</city>
        <zip>40000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerome Dimet</last_name>
      <email>jerome.dimet@ght40.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Carrouel F, Conte MP, Fisher J, Gonçalves LS, Dussart C, Llodra JC, Bourgeois D. COVID-19: A Recommendation to Examine the Effect of Mouthrinses with β-Cyclodextrin Combined with Citrox in Preventing Infection and Progression. J Clin Med. 2020 Apr 15;9(4). pii: E1126. doi: 10.3390/jcm9041126.</citation>
    <PMID>32326426</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2020</study_first_posted>
  <last_update_submitted>September 21, 2020</last_update_submitted>
  <last_update_submitted_qc>September 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Claude Bernard University</investigator_affiliation>
    <investigator_full_name>Carrouel Florence</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>covid19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>mouthrinses</keyword>
  <keyword>antiviral</keyword>
  <keyword>bêta-cyclodextrin</keyword>
  <keyword>citrox</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betadex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

